Multilineage Differentiation Potential of Equine Adipose-Derived Stromal/Stem Cells from Different Sources.
Stage HJ., Trappe S., Söllig K., Trachsel DS., Kirsch K., Zieger C.
Laboratory Study, published in Animals (Basel) (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Animals (Basel) (2023)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 37106915
- PMCID
- PMC10135324
- DOI
- 10.3390/ani13081352
- Citations
- 4
Abstract (original English)
The investigation of multipotent stem/stromal cells (MSCs) in vitro represents an important basis for translational studies in large animal models. The study's aim was to examine and compare clinically relevant in vitro properties of equine MSCs, which were isolated from abdominal (abd), retrobulbar (rb) and subcutaneous (sc) adipose tissue by collagenase digestion (ASCs- SVF ) and an explant technique (ASCs- EXP ). Firstly, we examined proliferation and trilineage differentiation and, secondly, the cardiomyogenic differentiation potential using activin A, bone morphogenetic protein-4 and Dickkopf-1. Fibroblast-like, plastic-adherent ASCs- SVF and ASCs- EXP were obtained from all sources. The proliferation and chondrogenic differentiation potential did not differ significantly between the isolation methods and localizations. However, abd-ASCs- EXP showed the highest adipogenic differentiation potential compared to rb- and sc-ASCs- EXP on day 7 and abd-ASCs- SVF a higher adipogenic potential compared to abd-ASCs- EXP on day 14. Osteogenic differentiation potential was comparable at day 14, but by day 21, abd-ASCs- EXP demonstrated a higher osteogenic potential compared to abd-ASCs- SVF and rb-ASCs- EXP . Cardiomyogenic differentiation could not be achieved. This study provides insight into the proliferation and multilineage differentiation potential of equine ASCs and is expecte
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.